Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2000 Mar 18;1(2):E8.
doi: 10.1208/pt010208.

Pramlintide injection drug product robustness studies

R A Kenley  1 , F Bancroft, J L'Italien, A Stepanenko, M Townsend, T Dixit
Affiliations

Pramlintide injection drug product robustness studies

R A Kenley et al. AAPS PharmSciTech. .

Abstract

The article examines the effects of temperature excursions and actual dose withdrawal on the quality of pramlintide injection, a multidose liquid parenteral formulation. Studies were designed to demonstrate product robustness under conditions that may occur during patient use. Pramlintide %Purity was determined by two high-performance liquid chromatography (HPLC) methods, a reversed-phase (RP-HPLC) and a strong-cation exchange (SCX-HPLC) method. A second RP-HPLC method was used to determine pramlintide potency and the concentration of the m-cresol preservative. Antimicrobial preservative effectiveness testing was per USP and European Pharmacopeia (Ph. Eur.). Short-term stability studies were undertaken to probe the effects of the following conditions: 5 degrees C to 40 degrees C and 5 degrees C to -20 degrees C temperature cycling over 10 days; once daily or four-times daily dose withdrawal over 12 or 42 days; and combined 30 degrees C storage and four-times daily dose withdrawal over 42 days. In all cases, pramlintide %Purity and potency values remained essentially unchanged or unchanged relative to controls. Similarly, product appearance, and m-cresol concentration and preservative effectiveness were not significantly affected by the stress conditions used in the 5 studies. Pramlintide injection drug product is extremely robust to challenging stress conditions that may occur during patient use of this multidose product for chronic administration.

PubMed Disclaimer

References

    1. Young A, Pittner R, Gedulin B, Vine W, Rink T. Amylin Regulation of carbohydrate metabolism. Biochem Soc Trans. 1995;23:325–331. - PubMed
    1. Scherbaum WA. The role of amylin in the physiology of glycemic control. Experimental and Clinical Endocrinol and Diabetes. 1998;106(2):97–102. doi: 10.1055/s-0029-1211958. - DOI - PubMed
    1. Amiel S. Amylin and diabetes. Lancet. 1993;341:1249–1250. doi: 10.1016/0140-6736(93)91153-D. - DOI - PubMed
    1. Janes S, Gaeta L, Beaumont K, Beeley K, Rink T. The selection of pramlintide for clinical evaluation. Diabetes. 1996;45(Suppl 2):235A–235A.
    1. Thompson RG, Gottlieb A, Organ K, Kolterman OG. Pramlintide, a human amylin analog reduced post-prandial plasma glucose, insulin and epeptide concentrations in patients with type II diabetes. Diabetic Medicine. 1997;14(7):547–555. doi: 10.1002/(SICI)1096-9136(199707)14:7<547::AID-DIA390>3.0.CO;2-U. - DOI - PubMed

MeSH terms

LinkOut - more resources